

Form PTO-1449 U.S. Department of Commerce 2004
(REV. 2-82) Patent and Trademark Office



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Atty. Docket No.
A31386-A - 070165.0593

Serial No.
09/855,886

Applicants
Collerl et al.

Filing Date
May 15, 2001

Group
1642

U.S. PATENT DOCUMENTS

*Exam. Init.		Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENT

		Document No.			Class	SubClass	Translator Yes No

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

		Taverna et al. (1997) "Is $\alpha 5$ integrin a tumor suppressor gene?", <i>Proceedings of the American Association for Cancer Research</i> 38: 290-291.
		Hynes et al. (1997) "Targeted mutations in integrins and their ligands: their implications for vascular biology", <i>Thrombosis and Haemostasis</i> 78: 83-87.
		Taverna et al. (2004) "Increased primary tumor growth in mice null for $\beta 3 - \beta 3/\beta 5$ -integrins or selectins", <i>PNAS</i> 101: 763-768.
		Trikha et al. (2002) "Multiple roles for platelet GPIIb/IIIa and $\alpha v\beta 3$ integrins in tumor growth, angiogenesis, and metastasis", <i>Cancer Research</i> 62: 2824-2833.
		Lincoff et al. (2001) "Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization", <i>Circulation</i> 104: 163-167.
		Dean J. Kereiakes (2003) "Inflammation as a therapeutic target; a unique role for abciximab", <i>Supplement to AHJ</i> 146: 1-4.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.